{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:34:29Z","timestamp":1740180869449,"version":"3.37.3"},"reference-count":54,"publisher":"Consilium Medicum","issue":"10","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>The prevalence of hyperprolactinemia in postmenopausal women is unknown and has been estimated as infrequent by many studies. Prolactinomas found after menopause are usually macroadenomas and remain unrecognized for a long time due to atypical clinical signs or their absence. The growth potential of prolactinomas persists after menopause, most of them are invasive and accompanied by high prolactin levels. Treatment with dopamine agonists is usually long-term, the goals of which are to reduce tumor size, normalize prolactin levels and the negative effects of hyperprolactinemia. Treatment with cabergoline makes it possible to achieve remission of the disease in the first years after discontinuation, however, the proportion of relapses in postmenopausal women increases 5 years after discontinuation of the drug. Remission of prolactinomas is not evident in postmenopausal women. The modern management of patients with prolactinoma and\/or hyperprolactinemia does not have clear positions in the postmenopausal period. Controversial issues remain: an ambiguous relationship between prolactin levels and breast cancer, there are no convincing conclusions on the improvement of bone mineral density and\/or a decrease in the risk of fractures with normalization of prolactin levels, there are no data on metabolic parameters after the end of treatment with dopamine agonists, conflicting information about the relationship of prolactin levels and the severity of the manifold manifestations of the climacteric syndrome. The use of estrogen-progestin drugs in women with hyperprolactinemia\/prolactinomas is also not well understood. Thus, the problem of hyperprolactinemia in the perimenopausal and postmenopausal period is underestimated and requires additional research, as well as the development of diagnostic and therapeutic strategies for potential benefits in terms of weight loss, improving insulin sensitivity, reducing the risk of fractures, maintaining sexuality and psycho-emotional well-being.<\/jats:p>","DOI":"10.26442\/00403660.2021.10.201073","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T18:35:47Z","timestamp":1636137347000},"page":"1234-1239","source":"Crossref","is-referenced-by-count":1,"title":["Hyperprolactinemia in the postmenopause: versions and contraversions"],"prefix":"10.26442","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5335-1248","authenticated-orcid":false,"given":"Olga Ya.","family":"Leshchenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"\u041c\u0435\u043b\u044c\u043d\u0438\u0447\u0435\u043d\u043a\u043e \u0413.\u0410., \u0414\u0437\u0435\u0440\u0430\u043d\u043e\u0432\u0430 \u041b.\u041a., \u041f\u0438\u0433\u0430\u0440\u043e\u0432\u0430 \u0415.\u0410., \u0438 \u0434\u0440. \u0424\u0435\u0434\u0435\u0440\u0430\u043b\u044c\u043d\u044b\u0435 \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u043f\u043e \u043a\u043b\u0438\u043d\u0438\u043a\u0435, \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435, \u0434\u0438\u0444\u0444\u0435\u0440\u0435\u043d\u0446\u0438\u0430\u043b\u044c\u043d\u043e\u0439 \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435 \u0438 \u043c\u0435\u0442\u043e\u0434\u0430\u043c \u043b\u0435\u0447\u0435\u043d\u0438\u044f \u0433\u0438\u043f\u0435\u0440\u043f\u0440\u043e\u043b\u0430\u043a\u0442\u0438\u043d\u0435\u043c\u0438\u0438. \u041f\u0440\u043e\u0431\u043b\u0435\u043c\u044b \u044d\u043d\u0434\u043e\u043a\u0440\u0438\u043d\u043e\u043b\u043e\u0433\u0438\u0438. 2013;59(6):19-26 [Melnichenko GA, Dzeranova LK, Pigarova EA, et al. Federal clinical recommendations for clinic, diagnostics, differential diagnosis and methods for treatment of hyperprolactinemia. Problemy endokrinologii. 2013;59(6):19-26 (in Russian)].","DOI":"10.14341\/probl201359619-26"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02562.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.14341\/omet2016214-19"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0250"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0767-5"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-010-0217-8"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-828X.2011.01321.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000494725"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Maiter D, Delgrange E. The challenges in managing giant prolactinomas. Eur J Endocrinol. 2014;170:R213-27.","DOI":"10.1530\/EJE-14-0013"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0503"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12418"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.14341\/probl200955626-31"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.02759.x"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1249"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-008-0097-3"},{"key":"ref17","unstructured":"\u0421\u043c\u0435\u0442\u043d\u0438\u043a \u0412.\u041f., \u041e\u0441\u0438\u043f\u043e\u0432\u0430 \u0410.\u0410. \u0413\u0438\u043f\u0435\u0440\u043f\u0440\u043e\u043b\u0430\u043a\u0442\u0438\u043d\u0435\u043c\u0438\u044f: \u0440\u0435\u0430\u043a\u0446\u0438\u044f \u043a\u043e\u0441\u0442\u043d\u043e\u0439 \u0442\u043a\u0430\u043d\u0438 \u0438 \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u043a\u0430\u0431\u0435\u0440\u0433\u043e\u043b\u0438\u043d\u043e\u043c. \u041f\u0440\u043e\u0431\u043b\u0435\u043c\u044b \u0440\u0435\u043f\u0440\u043e\u0434\u0443\u043a\u0446\u0438\u0438. 2000;6:24-9 [Smetnik VP, Osipova AA. Hyperprolactinemia: bone response and the effectiveness of cabergoline therapy. Problemy reproduktsii. 2000;6:24-9 (in Russian)]."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0293-4"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.22161"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0308-9"},{"key":"ref21","unstructured":"\u0414\u0437\u0435\u0440\u0430\u043d\u043e\u0432\u0430 \u041b.\u041a., \u041f\u0438\u0433\u0430\u0440\u043e\u0432\u0430 \u0415.\u0410., \u0412\u0430\u0441\u0438\u043b\u044c\u0435\u0432\u0430 \u0422.\u041e., \u0438 \u0434\u0440. \u0413\u0438\u043f\u0435\u0440\u043f\u0440\u043e\u043b\u0430\u043a\u0442\u0438\u043d\u0435\u043c\u0438\u044f \u0443 \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u043a\u0438 \u0441 \u0440\u0430\u0441\u043f\u0440\u043e\u0441\u0442\u0440\u0430\u043d\u0435\u043d\u043d\u044b\u043c \u0440\u0430\u043a\u043e\u043c \u043c\u043e\u043b\u043e\u0447\u043d\u043e\u0439 \u0436\u0435\u043b\u0435\u0437\u044b: \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0441\u043b\u0443\u0447\u0430\u0439. \u041e\u043f\u0443\u0445\u043e\u043b\u0438 \u0436\u0435\u043d\u0441\u043a\u043e\u0439 \u0440\u0435\u043f\u0440\u043e\u0434\u0443\u043a\u0442\u0438\u0432\u043d\u043e\u0439 \u0441\u0438\u0441\u0442\u0435\u043c\u044b. 2012;2:30-4 [Dzeranova LK, Pigarova EA, Vasilyeva TO, et al. Hyperprolactinemia in a patient with advanced breast cancer: a clinical case. Opukholi zhenskoy reproduktivnoy sistemy. 2012;2:30-4 (in Russian)]."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1530\/EC-17-0171"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2015.1053209"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/srep25998"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Medic Stojanoska M, Mitic G, Mitic I, et al. The influence of hyperprolactinemia on coagulation parameters in females with prolactinomas. Srp Arch Celok Lek. 2014;142:314-9.","DOI":"10.2298\/SARH1406314M"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(96)00075-6"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00403.x"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1470077"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1159\/000486000"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1159\/000486000"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0377-9"},{"key":"ref32","unstructured":"Leshchenko O, Zhukovets I, Atalyan A. Risk of obesity in adult women with hypothalamic dysfunction in puberty. Observational prospective study. Endocrine Reviews. 2017;38(S3):552."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.21103\/Article7(3)_OA10"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.14341\/omet9532"},{"key":"ref35","unstructured":"Schmid C, Goede D, Hauser R, Brandle M. Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly. 2006;136:254-8."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.20953\/1817-7646-2017-5-12-17"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2008.297"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2529"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0017"},{"key":"ref40","unstructured":"\u0428\u0438\u0448\u043a\u043e\u0432\u0430 \u0412.\u041d. \u041e\u0436\u0438\u0440\u0435\u043d\u0438\u0435 \u0438 \u0433\u0438\u043f\u0435\u0440\u043f\u0440\u043e\u043b\u0430\u043a\u0442\u0438\u043d\u0435\u043c\u0438\u044f. Consilium Medicum. 2010;12(12):3-6 [Shishkova VN. Obesity and hyperprolactinemia. Consilium Medicum. 2010;12(12):3-6 (in Russian)]."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-282x2000000400012"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2019.04.120"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2009.01629.x"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.29413\/ABS.2020-5.1.3"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.21103\/Article10(2)_OA15"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-66-4-868"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5122(94)90011-6"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1080\/09513590500279717"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Watanabe S, Akutsu H, Takano S, et al. Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal. Clin Endocrinol (Oxf). 2017;86(2):207-13. DOI:10,1111\/\u0441.13240","DOI":"10.1111\/cen.13240"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13765"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00038"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1238"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-012-9857-y"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01190.x"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/87137\/65319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/87137\/65319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T11:20:33Z","timestamp":1643023233000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/87137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":54,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,15]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2021.10.201073","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"type":"electronic","value":"2309-5342"},{"type":"print","value":"0040-3660"}],"subject":[],"published":{"date-parts":[[2021,10,15]]}}}